What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.
Authors
Affiliations (12)
Affiliations (12)
- Department of Radiology, NYU Grossman School of Medicine & NYU Langone Health, 660 1st Avenue, New York, NY, 10016, USA. [email protected].
- Department of Medical Images, Radiation Therapy, Oncology and Hematology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil.
- Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Radiology, Kawasaki Medical School, Okayama, Japan.
- Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, USA.
- Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
- Department of Radiation Oncology, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.
- Department of Radiology, NYU Grossman School of Medicine & NYU Langone Health, 660 1st Avenue, New York, NY, 10016, USA.
Abstract
Since the introduction of the Vesical Imaging-Reporting and Data System (VI-RADS), MRI has become an important imaging modality in the management of patients with bladder cancer. Its excellent diagnostic performance for determining muscle invasion in bladder cancer has been supported by numerous prospective and retrospective studies. Nevertheless, there needs to be continued improvement of the diagnostic performance of VI-RADS and sustained efforts to address remaining unmet clinical needs within the field of bladder cancer. In this paper, we highlight several such areas, some of which are actively being investigated. These include (1) whether to use intravenous contrast media or not (multiparametric vs. biparametric MRI), (2) quantitative metrics to enhance assessment of muscle invasion, (3) anatomic locations that come with pitfalls in staging, (4) introduction of bladder MRI image quality, (5) neoadjuvant chemotherapy VI-RADS (nacVI-RADS) and other considerations needed in the treatment response assessment after systemic therapies, (6) need for wider adoption, training, and implementation, and (7) application of artificial intelligence.